A complete study of Doxazosin characterization

Authors

  • Itamar Luís Gonçalves Laboratório de Síntese Orgânica Medicinal/LaSOM do Programa de Pós-Graduação em Ciências Farmacêuticas/PPGCF da Universidade Federal do Rio Grande do Sul image/svg+xml
    • Mariana Maier Gaelzer Programa de Pós-Graduação em Ciências Biológicas: Bioquímica do Instituto de Ciências Básicas da Saúde da Universidade Federal do Rio Grande do Sul image/svg+xml
      • Gabriel Oliveira de Azambuja Laboratório de Síntese Orgânica Medicinal/LaSOM do Programa de Pós-Graduação em Ciências Farmacêuticas/PPGCF da Universidade Federal do Rio Grande do Sul image/svg+xml
        • Christianne Gazzana Salbego Programa de Pós-Graduação em Ciências Biológicas: Bioquímica do Instituto de Ciências Básicas da Saúde da Universidade Federal do Rio Grande do Sul image/svg+xml
          • Vera Lucia Eifler-Lima Laboratório de Síntese Orgânica Medicinal/LaSOM do Programa de Pós-Graduação em Ciências Farmacêuticas/PPGCF da Universidade Federal do Rio Grande do Sul image/svg+xml

            DOI:

            https://doi.org/10.22456/2527-2616.73960

            Keywords:

            doxazosin, NMR, FT-IR, signals assignment

            Abstract

            Doxazosin is an important drug used to treat hypertension and prostatic hyperplasia. An enantiomeric (R)/(S) doxazosin
            mesylate mixture was complete characterized by NMR and additionally FT-IR spectroscopy techniques. Different NMR
            experiments were performed, such as APT, HSQC, and HMBC in order to confirm the NMR signals assignments. All the
            hydrogens and most of carbons atoms were assigned. In this context, the results reported here, consists in important
            information for identification and quality control of doxazosin mesylate.

            Downloads

            Download data is not yet available.

            References

            Wykretowicz, A., Guzik, P., Wysocki, H. Doxazosin in the current treatment of hypertension. Expert opinion on pharmacotherapy. 2008;9(4):625-33.

            Wilt, T.J., MacDonald, R. Doxazosin in the treatment of benign prostatic hypertrophy: an update. Clinical interventions in aging. 2006;1(4):389.

            Pfizer. Company History 2017 [cited 2017 20/07/2017]. Available from: http://www.pfizer.com/about/history/all.

            Gaelzer, M.M., Coelho, B.P., de Quadros, A.H., Hoppe, J.B., Terra, S.R., Guerra, M.C.B., et al. Phosphatidylinositol 3-Kinase/AKT pathway inhibition by doxazosin promotes glioblastoma cells death, upregulation of p53 and triggers low neurotoxicity. PloS one. 2016;11(4):e0154612.

            Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., Sukhatme, V.P., Vikas, P. The repurposing drugs in oncology (ReDO) project. ecancermedicalscience. 2014;8.

            González-Juanatey, J.R., Iglesias, M.J., Alcaide, C., Piñeiro, R., Lago, F. Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of α 1-adrenergic blockade. Circulation. 2003;107(1):127-31.

            Nikolic, K., Filipic, S., Smoliński, A., Kaliszan, R., Agbaba, D. Partial least square and hierarchical clustering in ADMET modeling: Prediction of blood– brain barrier permeation of α-adrenergic and imidazoline receptor ligands. Journal of Pharmacy & Pharmaceutical Sciences. 2013;16(4):622-47.

            Bakshi, M., Ojha, T., Singh, S. Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions. Journal of Pharmaceutical and Biomedical Analysis. 2004;34(1):19-26.

            Yuan, X-R., Liu, Y-H., Li, R-Y., Chen, X-X. Experimental and theoretical NMR study of (s)- doxazosin. Acta Physico-Chimica Sinica. 2008;24(6):1058-62.

            Loidreau, Y., Besson, T. Microwave-assisted thermal decomposition of formamide: a tool for coupling a pyrimidine ring with an aromatic partner. Tetrahedron. 2011;67(26):4852-7.

            Rouf, A., Aga, M.A., Kumar, B., Taneja, S.C. A facile approach to chiral 1, 4-benzodioxane toward the syntheses of doxazosin, prosympal, piperoxan, and dibozane. Tetrahedron Letters. 2013;54(48):6420-2.

            Tsyskovskaia, I., Kandil, M., Beaumier, Y. Synthesis of a New Doxazosin‐Related Compound. Synthetic communications. 2007;37(3):447-50.

            Zhang, L-Y., Wang, B-L., Zhan, Y-Z., Zhang, Y., Zhang, X., Li, Z-M. Synthesis and biological activities of some fluorine- and piperazine-containing 1,2,4- triazole thione derivatives. Chinese Chemical Letters. 2016;27(1):163-7.

            Koester, L.S., Guterres, S.S., Le Roch, M., EiflerLima, V.L., Zuanazzi, J.A., Bassani, V.L. Ofloxacin/βCyclodextrin Complexation. Drug Development and Industrial Pharmacy. 2001;27(6):533-40.

            Commission BP. British Pharmacopoeia. London2013.

            Pharmacopeia U. United States Pharmacopeia. The Standard USA: US Pharmacopeia 1995. 2002.

            Downloads

            Published

            28-08-2017 — Updated on 10-03-2026

            Versions

            How to Cite

            Gonçalves, I. L., Maier Gaelzer, M., Oliveira de Azambuja, G., Gazzana Salbego, C., & Eifler-Lima, V. L. (2026). A complete study of Doxazosin characterization. Drug Analytical Research, 1(1), 56–60. https://doi.org/10.22456/2527-2616.73960 (Original work published August 28, 2017)

            Issue

            Section

            ORIGINAL ARTICLES

            Similar Articles

            You may also start an advanced similarity search for this article.